BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells
Open Access
- 17 October 2013
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 122 (16) , 2864-2876
Abstract
Key Points: BCL-2 homology domain 3 mimetic inhibitor ABT-737 targets leukemia initiating cells and progenitors. Dephosphorylates RAS signaling proteins and regulates proliferation and differentiation genes detected by gene expression profiling.Keywords
This publication has 50 references indexed in Scilit:
- Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemiaGenes & Development, 2012
- RETRACTED ARTICLE: MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complexLeukemia, 2011
- Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expressionCancer Biology & Therapy, 2010
- Roles for the type III TGF-β receptor in human cancerCellular Signalling, 2010
- Splicing factor and exon profiling across human tissuesNucleic Acids Research, 2010
- In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomasProceedings of the National Academy of Sciences, 2008
- Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung CancerCancer Research, 2008
- DNA profiling by arrayCGH in acute myeloid leukemia and myelodysplastic syndromesCytogenetic and Genome Research, 2007
- The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedCancer Cell, 2006
- Osteopontin is upregulated by BCR-ABLBiochemical and Biophysical Research Communications, 2005